Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Tumor Lysis Syndrome × Oxidoreductases × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1 Hematologic Neoplasms 1

Interventions

rasburicase 8 Urate Oxidase 4 Allopurinol 3 venetoclax 1 obinutuzumab 1 alvocidib 1 Uric Acid 1 Pegloticase 1 Oxidoreductases 1 Lenalidomide 1 Febuxostat 1 Carbamates 1 Bendamustine Hydrochloride 1 Amides 1 AZD0466 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04745910 2025-12-18

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Active not recruiting

Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡